ANI Pharmaceuticals (ANIP) News Today $69.55 +0.83 (+1.21%) Closing price 04:00 PM EasternExtended Trading$69.54 -0.01 (-0.01%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Bank of Montreal Can Acquires 8,257 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Bank of Montreal Can lifted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 230,153 shares of the specialty pharmaceutical coApril 15 at 4:57 AM | marketbeat.comRussell Investments Group Ltd. Sells 17,462 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Russell Investments Group Ltd. cut its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 11.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 140,496 shares of the specialty pharmaceutical company's sApril 15 at 4:41 AM | marketbeat.comMartingale Asset Management L P Sells 8,563 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Martingale Asset Management L P lessened its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 24.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,177 shares of the specialty pharmaceutical companyApril 14 at 5:23 AM | marketbeat.comJPMorgan Chase & Co. Sells 286,785 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)JPMorgan Chase & Co. decreased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 51.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 268,050 shares of the specialty pharmaceutical cApril 14 at 3:29 AM | marketbeat.comGuggenheim Reaffirms "Buy" Rating for ANI Pharmaceuticals (NASDAQ:ANIP)April 14 at 2:58 AM | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Given Buy Rating at GuggenheimGuggenheim restated a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Friday.April 13 at 10:16 AM | marketbeat.comLeerink Partnrs Weighs in on ANIP Q1 EarningsANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of ANI Pharmaceuticals in a research note issued to investors on Wednesday, April 9th. Leerink Partnrs analyst F. Khurshid anticipates that the speciaApril 13 at 7:28 AM | marketbeat.comF M Investments LLC Trims Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)F M Investments LLC decreased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 8.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,313 shares of the specialty pharmaceutical company's stockApril 13 at 6:27 AM | marketbeat.comVanguard Group Inc. Lowers Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Vanguard Group Inc. lowered its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 2.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,314,372 shares of the specialty pharmaceutical company's stock after selliApril 13 at 3:40 AM | marketbeat.comGuggenheim Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP)April 12 at 3:00 AM | markets.businessinsider.comWhat is Leerink Partnrs' Forecast for ANIP Q1 Earnings?April 12 at 1:25 AM | americanbankingnews.comDeep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)April 11, 2025 | benzinga.comRanger Investment Management L.P. Has $31.94 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Ranger Investment Management L.P. reduced its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 2.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 577,738 shares of the specialty pharmaApril 11, 2025 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Downgraded by StockNews.com to "Sell"StockNews.com cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday.April 10, 2025 | marketbeat.comANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ETApril 9, 2025 | globenewswire.comHeadlands Technologies LLC Has $66,000 Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Headlands Technologies LLC lessened its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 85.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,198 shares of the specialty pharmaceutical coApril 9, 2025 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.comApril 9, 2025 | americanbankingnews.comIntegrated Quantitative Investments LLC Buys Shares of 4,900 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Integrated Quantitative Investments LLC purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,900 shares of the specialty phaApril 8, 2025 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Holdings Decreased by American Century Companies Inc.American Century Companies Inc. lessened its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 31.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 60,248 shares of the specialty pharmaceutical company's stocApril 8, 2025 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Rating of "Buy" by BrokeragesShares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) have received a consensus recommendation of "Buy" from the nine brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have issuApril 7, 2025 | marketbeat.comANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual ConferenceMarch 31, 2025 | globenewswire.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Loomis Sayles & Co. L PLoomis Sayles & Co. L P increased its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 11.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,185 shares of the specMarch 31, 2025 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Up 3.1% - Here's What HappenedANI Pharmaceuticals (NASDAQ:ANIP) Stock Price Up 3.1% - Here's WhyMarch 27, 2025 | marketbeat.comRaymond James Financial Inc. Acquires New Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Raymond James Financial Inc. acquired a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 70,826 shares of the specialty pharmaceutical company's stock, valued at approximatelyMarch 27, 2025 | marketbeat.comIntech Investment Management LLC Has $983,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Intech Investment Management LLC raised its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 41.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,780 shares of the specialty pharmaceutical compMarch 23, 2025 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by AlphaQuest LLCAlphaQuest LLC decreased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 94.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 516 shares of the specialty pharmaceutical company's stock after selling 9,377 shares dMarch 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Trims Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Charles Schwab Investment Management Inc. reduced its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 5.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 236,157 shares of the specialty phaMarch 22, 2025 | marketbeat.comANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces the Launch of Nitazoxanide TabletsMarch 19, 2025 | finanznachrichten.deANI Pharmaceuticals launches Nitazoxanide Tablets, 500 mg.March 19, 2025 | markets.businessinsider.comANI Pharmaceuticals Announces the Launch of Nitazoxanide TabletsMarch 19, 2025 | globenewswire.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Increased by William Blair Investment Management LLCWilliam Blair Investment Management LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48March 19, 2025 | marketbeat.comANI Pharmaceuticals announces royalty obligation buyout for Iluvien, YutiqMarch 19, 2025 | markets.businessinsider.comANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN and YUTIQMarch 18, 2025 | finanznachrichten.deANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®March 18, 2025 | finance.yahoo.comANI Pharmaceuticals' (ANIP) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday.March 18, 2025 | marketbeat.comANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®March 18, 2025 | globenewswire.comBank of New York Mellon Corp Increases Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Bank of New York Mellon Corp lifted its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 123,832 shares of the speciaMarch 16, 2025 | marketbeat.comANI Pharmaceuticals (NASDAQ:ANIP) Upgraded at StockNews.comStockNews.com raised shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Friday.March 15, 2025 | marketbeat.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of StockANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.March 15, 2025 | marketbeat.comJefferies Initiates Coverage of ANI Pharmaceuticals (ANIP) with Buy RecommendationMarch 15, 2025 | msn.comANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Jefferies Financial GroupJefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research note on Friday. They issued a "buy" rating and a $80.00 price objective on the stock.March 15, 2025 | marketbeat.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 400 SharesMarch 15, 2025 | insidertrades.comANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN LabelMarch 14, 2025 | finanznachrichten.deANI Pharmaceuticals initiated with a Buy at JefferiesMarch 14, 2025 | markets.businessinsider.comANI Pharmaceuticals announces FDA approval for expansion of Iluvien labelMarch 14, 2025 | markets.businessinsider.comThompson Siegel & Walmsley LLC Increases Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Thompson Siegel & Walmsley LLC grew its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 23.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 283,860 shares of the specialty pharmaceutical company's stock afterMarch 14, 2025 | marketbeat.comANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® LabelMarch 14, 2025 | globenewswire.comJP Morgan Initiates Coverage of ANI Pharmaceuticals (ANIP) with Overweight RecommendationMarch 13, 2025 | msn.comANI Pharmaceuticals initiated with an Overweight at JPMorganMarch 12, 2025 | markets.businessinsider.comANI Pharmaceuticals (NASDAQ:ANIP) Now Covered by Analysts at JPMorgan Chase & Co.JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a report on Wednesday. They set an "overweight" rating and a $85.00 price target for the company.March 12, 2025 | marketbeat.com Remove Ads Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Media Mentions By Week ANIP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIP News Sentiment▼0.950.80▲Average Medical News Sentiment ANIP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIP Articles This Week▼236▲ANIP Articles Average Week Remove Ads Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Legend Biotech News Telix Pharmaceuticals Limited American Depositary Shares News Sarepta Therapeutics News Blueprint Medicines News Axsome Therapeutics News Nuvalent News ADMA Biologics News Krystal Biotech News Grifols News Cytokinetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIP) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANIP Stock Free ANIP Stock Alerts